Instem Life Sciences, a software provider to the healthcare industry, said several contracts needed to meet revenue and profit expectations for the year remain pending.
The group, which previously cautioned that research organisations, which make up the bulk of its client base, are being cautious in software investment, has seen its share price plunge 57% in the last 12 months.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
-
End of “fleecehold”: Will leasehold reforms bring an end to the UK's feudal system?Britain’s feudal system of property ownership is being overhauled. It's about time, says Simon Wilson
-
Microsoft’s partnership with OpenAI is on the rocksMicrosoft’s joint venture with OpenAI, the developer of ChatGPT, appears to be in trouble. What now for the two groups?
